Liquid biopsy system

The PlaqueTec Liquid Biopsy System™ (LBS) is a revolutionary sample capture system specifically designed to reliably collect samples relevant to coronary vascular function and plaque progression.

The LBS addresses the underlying biomarker collection problems preventing advances in CAD research:

LBS is designed to collect samples from the first 100 mm of the coronary arteries, the primary location for plaque rupture leading to death;

Person to person variation in background biomarker noise is eliminated by capturing multiple samples simultaneously from the coronary arteries, upstream and downstream of coronary plaques; and

Inefficient sampling of plaque biomarker release, caused by the boundary layer effect, is overcome, allowing accurate biomarker information to be collected for the first time.

Local sampling from the disease site

Biomarkers released from plaques are the most likely indicator of plaque activity and event risk.  The LBS is designed to quickly and reliably take samples representative of the first 100 mm of the coronary vasculature, upstream and downstream of the plaque.

Sample normalisation removes person-to-person variability

The LBS takes multiple simultaneous samples from along the length of a coronary artery, with the most upstream sample acting as the reference.  Data from the reference sample are used to eliminate background noise, with the remaining samples being used to accurately determine in-artery changes (gradients) in biomarker levels.  This gradient approach not only avoids the issue of variability between individuals (seen when testing conventional blood samples), it also easily and unequivocally identifies which of the many putative biomarkers are locally elevated at the most critical site of disease.

In-artery mixing ensures effective plaque sampling

PlaqueTec’s research has shown that biomarkers released from regions of inflammation in the artery walls (plaques) remain near the walls of the artery and do not readily mix with the bulk blood flow, due to the boundary layer effect.  Existing tools do not address the boundary layer and so collect predominantly bulk blood flow which is free of biomarkers released by local plaques.  The LBS deploys compliant mixing elements into the artery ensuring that the biomarkers released at the wall are mixed into the bulk flow where it can be collected.

The unparalleled resolution of the LBS has the potential to transform the understanding and treatment of cardiovascular disease.